{"DataElement":{"publicId":"6464633","version":"1","preferredName":"Acute Myeloid Leukemia with Recurrent Genetic Abnormalities Classification Type","preferredDefinition":"Information related to the type of classification of acute myeloid leukemia with recurrent genetic abnormalities.","longName":"6464632v1.0:6462807v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"6464632","version":"1","preferredName":"Acute Myeloid Leukemia with Recurrent Genetic Abnormalities Classification","preferredDefinition":"A group of acute myeloid leukemias characterized by recurrent genetic abnormalities, mainly balanced translocations.  (WHO, 2001)_A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"6464630v1.0:2321361v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"6464630","version":"1","preferredName":"Acute Myeloid Leukemia with Recurrent Genetic Abnormalities","preferredDefinition":"A group of acute myeloid leukemias characterized by recurrent genetic abnormalities, mainly balanced translocations.  (WHO, 2001)","longName":"C7175","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Recurrent Genetic Abnormalities","conceptCode":"C7175","definition":"A group of acute myeloid leukemias characterized by recurrent genetic abnormalities, mainly balanced translocations.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77694C35-395B-4A2E-E053-F662850A1937","latestVersionIndicator":"Yes","beginDate":"2018-10-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"ONEDATA","dateModified":"2018-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321361","version":"1","preferredName":"Classification","preferredDefinition":"Classification; the grouping of things into classes or categories.","longName":"C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-20AF-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77694C35-3969-4A2E-E053-F662850A1937","latestVersionIndicator":"Yes","beginDate":"2018-10-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"MORENOC","dateModified":"2018-11-01","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6462807","version":"1","preferredName":"Acute Myeloid Leukemia Classification Type","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001)._Something distinguishable as an identifiable class based on common qualities._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics._Something distinguishable as an identifiable class based on common qualities.","longName":"6462807v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"AML (megakaryoblastic) with t(1;22) (p13.3;q13.3); RBM15-MKL1","valueDescription":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1","ValueMeaning":{"publicId":"4358932","version":"1","preferredName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1","longName":"4358932","preferredDefinition":"An acute myeloid leukemia associated with t(1;22)(p13.3;q13.3) resulting in the expression of RBM15-MKL1 fusion protein. It affects infants and children and usually shows megakaryocytic maturation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia (Megakaryoblastic) with t(1;22)(p13.3;q13.1); RBM15-MKL1","conceptCode":"C82427","definition":"An acute myeloid leukemia associated with t(1;22)(p13.3;q13.1) resulting in the expression of RBM15-MKL1 fusion protein. It affects infants and children and usually shows megakaryocytic maturation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC1DCF52-8398-EF2F-E040-BB89AD435755","latestVersionIndicator":"Yes","beginDate":"2014-06-18","endDate":null,"createdBy":"NYCHM","dateCreated":"2014-06-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77690077-E6DB-3CAC-E053-F662850ADB47","beginDate":"2014-06-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"ONEDATA","dateModified":"2018-10-04","deletedIndicator":"No"},{"value":"Provisional entity: AML with BCR-ABL1","valueDescription":"Acute Myeloid Leukemia with BCR-ABL1","ValueMeaning":{"publicId":"5578258","version":"1","preferredName":"Acute Myeloid Leukemia with BCR-ABL1","longName":"5578258","preferredDefinition":"A rare, de novo acute myeloid leukemia in which the blasts harbor BCR-ABL1 translocation in the absence of a history and clinical and laboratory features of chronic myelogenous leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with BCR-ABL1","conceptCode":"C129785","definition":"A rare, de novo acute myeloid leukemia in which the blasts harbor BCR-ABL1 translocation in the absence of a history and clinical and laboratory features of chronic myelogenous leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41817DF1-B3CC-6EFE-E053-F662850A0613","latestVersionIndicator":"Yes","beginDate":"2016-11-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77690077-E6EF-3CAC-E053-F662850ADB47","beginDate":"2016-11-17","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"ONEDATA","dateModified":"2018-10-04","deletedIndicator":"No"},{"value":"AML with biallelic mutations of CEBPA","valueDescription":"Acute Myeloid Leukemia with Biallelic Mutations of CEBPA","ValueMeaning":{"publicId":"5578253","version":"1","preferredName":"Acute Myeloid Leukemia with Biallelic Mutations of CEBPA","longName":"5578253","preferredDefinition":"An acute myeloid leukemia with double mutations of the CEBPA gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Biallelic CEBPA Mutation","conceptCode":"C129782","definition":"An acute myeloid leukemia with double mutations of the CEBPA gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41817DF1-B3A7-6EFE-E053-F662850A0613","latestVersionIndicator":"Yes","beginDate":"2016-11-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77690077-E6F9-3CAC-E053-F662850ADB47","beginDate":"2016-11-17","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"ONEDATA","dateModified":"2018-10-04","deletedIndicator":"No"},{"value":"AML with inv(16)(p13.1;1q22) or t(16;16)(p13.1; q22); CBFB-MYH11","valueDescription":"Acute Myeloid Leukemia with Abnormal Marrow Eosinophils","ValueMeaning":{"publicId":"2672718","version":"1","preferredName":"Acute Myeloid Leukemia with Abnormal Marrow Eosinophils","longName":"2672718","preferredDefinition":"An acute myeloid leukemia with monocytic and granulocytic differentiation and the presence of a characteristically abnormal eosinophil component in the bone marrow.  This type of acute myeloid leukemia has a favorable prognosis.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11","conceptCode":"C9287","definition":"An acute myeloid leukemia with monocytic and granulocytic differentiation and the presence of a characteristically abnormal eosinophil component in the bone marrow.  This type of acute myeloid leukemia has a favorable prognosis.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37BBBFE3-F14A-60D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77690077-E703-3CAC-E053-F662850ADB47","beginDate":"2007-09-17","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"ONEDATA","dateModified":"2018-10-04","deletedIndicator":"No"},{"value":"AML with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM","valueDescription":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM","ValueMeaning":{"publicId":"3257032","version":"1","preferredName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM","longName":"3257032","preferredDefinition":"An acute myeloid leukemia associated with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM","conceptCode":"C82426","definition":"An acute myeloid leukemia associated with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A1E8-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77690077-E70D-3CAC-E053-F662850ADB47","beginDate":"2013-10-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"ONEDATA","dateModified":"2018-10-04","deletedIndicator":"No"},{"value":"AML with mutated NPM1","valueDescription":"Acute Myeloid Leukemia with Mutated NPM1","ValueMeaning":{"publicId":"3257028","version":"1","preferredName":"Acute Myeloid Leukemia with Mutated NPM1","longName":"3257028","preferredDefinition":"An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with NPM1 Mutation","conceptCode":"C82431","definition":"An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A19C-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77690077-E717-3CAC-E053-F662850ADB47","beginDate":"2016-11-15","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"ONEDATA","dateModified":"2018-10-04","deletedIndicator":"No"},{"value":"Provisional entity: AML with mutated RUNX1","valueDescription":"Acute Myeloid Leukemia with Mutated RUNX1","ValueMeaning":{"publicId":"5578252","version":"1","preferredName":"Acute Myeloid Leukemia with Mutated RUNX1","longName":"5578252","preferredDefinition":"De novo acute myeloid leukemia with RUNX1 gene mutation, not associated with myelodysplastic syndrome-related cytogenetic abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with RUNX1 Mutation","conceptCode":"C129786","definition":"Acute myeloid leukemia characterized by the presence of RUNX1 gene mutation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41817DF1-B382-6EFE-E053-F662850A0613","latestVersionIndicator":"Yes","beginDate":"2016-11-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77690077-E72B-3CAC-E053-F662850ADB47","beginDate":"2016-11-17","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"ONEDATA","dateModified":"2018-10-04","deletedIndicator":"No"},{"value":"AML with t(6;9) (p23;q34.1); DEK-NUP214","valueDescription":"Acute Myeloid Leukemia with t(6;9)(p23;q34.1); DEK-NUP214","ValueMeaning":{"publicId":"3257034","version":"1","preferredName":"Acute Myeloid Leukemia with t(6;9)(p23;q34.1); DEK-NUP214","longName":"3257034","preferredDefinition":"An acute myeloid leukemia associated with t(6;9)((p23;q34.1) resulting in DEK-NUP214(CAN) fusion protein expression. It is often associated with multilineage dysplasia and basophilia. It affects both children and adults and it usually has an unfavorable clinical outcome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with t(6;9)(p22.3;q34.1); DEK-NUP214","conceptCode":"C82423","definition":"An acute myeloid leukemia associated with t(6;9)(p22.3;q34.1) resulting in DEK-NUP214(CAN) fusion protein expression. It is often associated with multilineage dysplasia and basophilia. It affects both children and adults and it usually has an unfavorable clinical outcome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A89D3C60-A20E-6E25-E040-BB89AD433A3A","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77690077-E735-3CAC-E053-F662850ADB47","beginDate":"2013-10-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"ONEDATA","dateModified":"2018-10-04","deletedIndicator":"No"},{"value":"AML with t(8;21); (q22; q22.1); RUNX1-RUNX1T1","valueDescription":"Acute Myeloid Leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1","ValueMeaning":{"publicId":"2672720","version":"1","preferredName":"Acute Myeloid Leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1","longName":"2672720","preferredDefinition":"An acute myeloid leukemia with t(8;21)(q22;q22.1) giving rise to RUNX1/RUNX1T1 fusion transcript and showing maturation in the neutrophil lineage. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules. This type of AML is associated with good response to chemotherapy and high complete remission rate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1","conceptCode":"C9288","definition":"An acute myeloid leukemia with t(8;21)(q22; q22.1) giving rise to RUNX1/RUNX1T1 fusion transcript and showing maturation in the neutrophil lineage. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules. This type of AML is associated with good response to chemotherapy and high complete remission rate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37BBBFE3-F172-60D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77690077-E73F-3CAC-E053-F662850ADB47","beginDate":"2007-09-17","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"ONEDATA","dateModified":"2018-10-04","deletedIndicator":"No"},{"value":"AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","valueDescription":"Acute Myeloid Leukemia with t(9;11)(p22.3;q23.3); MLLT3-KMT2A","ValueMeaning":{"publicId":"3926632","version":"1","preferredName":"Acute Myeloid Leukemia with t(9;11)(p22.3;q23.3); MLLT3-KMT2A","longName":"3926632","preferredDefinition":"An acute myeloid leukemia associated with t(9;11)(p22.3;q23.3) and MLLT3-KMT2A fusion protein expression. Morphologically it usually has monocytic features. It may present at any age but it is more commonly seen in children. Patients may present with disseminated intravascular coagulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A","conceptCode":"C82403","definition":"An acute myeloid leukemia associated with t(9;11)(p21.3;q23.3) and MLLT3-KMT2A fusion protein expression. Morphologically it usually has monocytic features. It may present at any age but it is more commonly seen in children. Patients may present with disseminated intravascular coagulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E95A151A-B5AC-8777-E040-BB89AD433AA9","latestVersionIndicator":"Yes","beginDate":"2013-10-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77690077-E753-3CAC-E053-F662850ADB47","beginDate":"2018-10-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"ONEDATA","dateModified":"2018-10-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6462806","version":"1","preferredName":"Acute Myeloid Leukemia Classification Type","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).:A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.:Something distinguishable as an identifiable class based on common qualities.","longName":"C3171:C25161:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77690077-E6B3-3CAC-E053-F662850ADB47","latestVersionIndicator":"Yes","beginDate":"2018-10-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"ONEDATA","dateModified":"2018-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77690077-E6C4-3CAC-E053-F662850ADB47","latestVersionIndicator":"Yes","beginDate":"2018-10-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"MORENOC","dateModified":"2018-11-01","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"recurrent genetic abnormality","type":"Preferred Question Text","description":"recurrent genetic abnormality classification","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77698CB2-D18B-4F50-E053-F662850AA285","latestVersionIndicator":"Yes","beginDate":"2018-10-04","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-04","modifiedBy":"MORENOC","dateModified":"2018-11-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}